IL325858A - מתווכי הפעלה של תאי t כנגד cthrc1 ושיטות השימוש בהם - Google Patents

מתווכי הפעלה של תאי t כנגד cthrc1 ושיטות השימוש בהם

Info

Publication number
IL325858A
IL325858A IL325858A IL32585826A IL325858A IL 325858 A IL325858 A IL 325858A IL 325858 A IL325858 A IL 325858A IL 32585826 A IL32585826 A IL 32585826A IL 325858 A IL325858 A IL 325858A
Authority
IL
Israel
Prior art keywords
cthrc1
methods
same
cell engagers
engagers
Prior art date
Application number
IL325858A
Other languages
English (en)
Inventor
Christopher Harvey
Max London
Michael Briskin
Nikolai Suslov
Original Assignee
Phenomic Ai
Christopher Harvey
Max London
Michael Briskin
Nikolai Suslov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomic Ai, Christopher Harvey, Max London, Michael Briskin, Nikolai Suslov filed Critical Phenomic Ai
Publication of IL325858A publication Critical patent/IL325858A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL325858A 2023-07-12 2024-07-12 מתווכי הפעלה של תאי t כנגד cthrc1 ושיטות השימוש בהם IL325858A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363526444P 2023-07-12 2023-07-12
PCT/US2024/037940 WO2025015320A2 (en) 2023-07-12 2024-07-12 Anti-cthrc1 t cell engagers and methods of using the same

Publications (1)

Publication Number Publication Date
IL325858A true IL325858A (he) 2026-03-01

Family

ID=94216496

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325858A IL325858A (he) 2023-07-12 2024-07-12 מתווכי הפעלה של תאי t כנגד cthrc1 ושיטות השימוש בהם

Country Status (3)

Country Link
AU (1) AU2024293963A1 (he)
IL (1) IL325858A (he)
WO (1) WO2025015320A2 (he)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2020250204A1 (ko) * 2019-06-13 2020-12-17 프레스티지 바이오파마 피티이. 엘티디. 신규 cthrc1에 특이적 항체 및 이의 용도
TWI910146B (zh) * 2020-04-14 2026-01-01 法商施維雅藥廠 抗flt3抗體及組合物

Also Published As

Publication number Publication date
AU2024293963A1 (en) 2026-02-26
WO2025015320A2 (en) 2025-01-16
WO2025015320A3 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
EP3962939A4 (en) MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM
EP3635802A4 (en) MATERIALS FOR ELECTROCHEMICAL CELLS AND THEIR MANUFACTURING AND USE PROCESSES
SG11202109589VA (en) T cell receptors and methods of use thereof
ZA202203272B (en) Anti-stem cell factor antibodies and methods of use thereof
SG11202109588RA (en) T cell receptors and methods of use thereof
SG11202109593SA (en) T cell receptors and methods of use thereof
EP3935175A4 (en) T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
GB202019623D0 (en) Electrochemical methods and materials
IL325858A (he) מתווכי הפעלה של תאי t כנגד cthrc1 ושיטות השימוש בהם
IL315187A (he) תאי מטה ופאנל מטאמטרי אקוסטי הכולל לפחות תא מטא אקוסטי אחד
EP4203978A4 (en) MODIFIED B CELLS AND METHODS OF USE THEREOF
IL290228A (he) קולטנים לתאי t ושיטות לשימוש שלהם
IL290221A (he) קולטנים לתאי t ושיטות לשימוש שלהם
EP3529396A4 (en) ELECTROCHEMICAL CELL AND ITS PROCESS FOR USE
CA3298347A1 (en) Anti-cthrc1 t cell engagers and methods of using the same
GB202111039D0 (en) Materials and methods
EP3891488A4 (en) CELLULAR SCANNING TECHNOLOGIES AND METHODS OF USE THEREOF
SG10201909544YA (en) Genetically Modified T Cells And Uses Thereof
IL289564A (he) תאים שעברו שינוי ושיטות קשורות
GB2590770B (en) Cell stacks and methods of alignment
GB202211784D0 (en) Methods and uses
GB202101160D0 (en) Materials and methods
SG11202109595TA (en) T cell receptors and methods of use thereof
IL326330A (he) תאים שעברו מודיפיקציה ושימושים בהם
IL316481A (he) נוגדני sars-cov-2 ושיטות שימוש באותם